Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas

Emmanuel T. Akporiaye; Deborah Bradley-Dunlop; Sandra J. Gendler; Pinku Mukherjee; Cathy S. Madsen; Tobias Hahn; David G. Besselsen; Sharon M. Dial; Haiyan Cui; Katrina Trevor

doi:10.1016/j.vaccine.2007.06.063

Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas

Emmanuel T. Akporiaye, Deborah Bradley-Dunlop, Sandra J. Gendler, Pinku Mukherjee, Cathy S. Madsen, Tobias Hahn, David G. Besselsen, Sharon M. Dial, Haiyan Cui, Katrina Trevor

Biochemistry and Molecular Biology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/^MIN/+ (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-γ secretion by lymphocytes.

Original language	English (US)
Pages (from-to)	6965-6974
Number of pages	10
Journal	Vaccine
Volume	25
Issue number	39-40
DOIs	https://doi.org/10.1016/j.vaccine.2007.06.063
State	Published - Sep 28 2007

Keywords

Adenoma
Immunotherapy
MUC1.Tg/MIN mice

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2007.06.063

Cite this

@article{8ccf0e9fbad74f61af2743011d04cda6,

title = "Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas",

abstract = "A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/MIN/+ (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-γ secretion by lymphocytes.",

keywords = "Adenoma, Immunotherapy, MUC1.Tg/MIN mice",

author = "Akporiaye, {Emmanuel T.} and Deborah Bradley-Dunlop and Gendler, {Sandra J.} and Pinku Mukherjee and Madsen, {Cathy S.} and Tobias Hahn and Besselsen, {David G.} and Dial, {Sharon M.} and Haiyan Cui and Katrina Trevor",

note = "Funding Information: This work was supported by the SPORE in Gastrointestinal Cancers grant NIH CA#95060 (E. Gerner, P.I.). We gratefully acknowledge the technical assistance of the following individuals: Kristi Wirths, Jose Padilla, Phil Namaguchi, Jane Criswell, Karen Blohm-Mangone and Terese L. Tinder. In addition, critical discussions with Dr. Douglas Lake were much appreciated.",

year = "2007",

month = sep,

day = "28",

doi = "10.1016/j.vaccine.2007.06.063",

language = "English (US)",

volume = "25",

pages = "6965--6974",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "39-40",

}

TY - JOUR

T1 - Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas

AU - Akporiaye, Emmanuel T.

AU - Bradley-Dunlop, Deborah

AU - Gendler, Sandra J.

AU - Mukherjee, Pinku

AU - Madsen, Cathy S.

AU - Hahn, Tobias

AU - Besselsen, David G.

AU - Dial, Sharon M.

AU - Cui, Haiyan

AU - Trevor, Katrina

N1 - Funding Information: This work was supported by the SPORE in Gastrointestinal Cancers grant NIH CA#95060 (E. Gerner, P.I.). We gratefully acknowledge the technical assistance of the following individuals: Kristi Wirths, Jose Padilla, Phil Namaguchi, Jane Criswell, Karen Blohm-Mangone and Terese L. Tinder. In addition, critical discussions with Dr. Douglas Lake were much appreciated.

PY - 2007/9/28

Y1 - 2007/9/28

N2 - A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/MIN/+ (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-γ secretion by lymphocytes.

AB - A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/MIN/+ (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-γ secretion by lymphocytes.

KW - Adenoma

KW - Immunotherapy

KW - MUC1.Tg/MIN mice

UR - http://www.scopus.com/inward/record.url?scp=34548574821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548574821&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.06.063

DO - 10.1016/j.vaccine.2007.06.063

M3 - Article

C2 - 17707958

AN - SCOPUS:34548574821

SN - 0264-410X

VL - 25

SP - 6965

EP - 6974

JO - Vaccine

JF - Vaccine

IS - 39-40

ER -

Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this